Advances in Pediatric Therapeutic Drug Monitoring

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Pharmacy

Background:

• Therapeutic drug monitoring (TDM) is crucial for drugs with narrow therapeutic indices to balance efficacy and toxicity.
• Pediatric TDM innovation lags due to data scarcity and logistical challenges.
• Vancomycin, a key antibiotic for gram-positive infections, has historically relied on trough concentration monitoring in children.

Purpose of the Study:

• To review advancements in pediatric TDM, focusing on vancomycin as a model.
• To highlight the shift from trough-based to AUC-based vancomycin monitoring in pediatric populations.
• To discuss the implications of AUC-guided TDM for neonates and children.

Main Methods:

• Review of recent literature on vancomycin TDM in pediatric populations.
• Comparison of TDM approaches in infectious diseases.
• Analysis of pharmacokinetic (PK) modeling and flexible sampling strategies.

Main Results:

• Emerging data indicate vancomycin troughs are unreliable for predicting efficacy or toxicity.
• Trough-based vancomycin monitoring is linked to increased nephrotoxicity without clinical benefit.
• Area under the concentration-time curve (AUC) is the preferred metric for vancomycin exposure.

Conclusions:

• Consensus guidelines recommend transitioning to AUC-guided vancomycin monitoring for all age groups, including neonates and children.
• AUC-guided TDM offers optimal vancomycin exposure assessment, improving outcomes.
• Implementation of AUC-guided TDM in pediatrics presents opportunities and challenges.